Integrated product development (IPD) offers a way to mitigate the many issues that slow down the process of bringing a drug to market. A tendency to think of drug development as sequential and phase-driven means different activities are conducted in functional silos, which adversely affects the process.
In a recent BioProcess International special report, Mark Lane, Vice President of Development Consulting and Scientific Affairs at PharmaLex, explores how a global IPD program drives integrated collaboration and is an essential tool for improving efficiency, shortening timelines, reducing costs and improving the probability of regulatory approval and success in the marketplace. Download the special report to learn more.
